[Efficacy and safety of tandospirone in the treatment of patients with anxiety disorder].
OBJECTIVE
To explore the efficacy and safety of tandospirone for adolescents with anxiety disorder.


METHODS
In this multicenter open-label 12-week study, a total of 169 adolescents met the criteria of DSM-IV for anxiety disorder were treated with flexible dose of tandospirone. The effects and safety of treatment were assessed by the Hamilton anxiety scale (HAMA), state-trait anxiety inventory (STAI), clinical global impression (CGI) and side effects at baseline and Weeks 2, 4, 8 and 12.


RESULTS
In 151 cases completing the 12-week treatment, the scores of HAMA decreased by 18% ± 12%, 38% ± 16%, 54% ± 20% and 63% ± 17% at Weeks 2, 4, 8 and 12. Significant reductions in HAMA scores were seen at Weeks 2-12 (P < 0.01) and marked improvement appeared in 81.5% cases at Week 12 (reduction rate of HAMA: 50%). At Week 12, the HAMD(17) scores were markedly lower versus baseline (7 ± 2 vs 13 ± 3, P < 0.01). Adverse effect of tandospirone was scarcely found (9.9%).


CONCLUSIONS
Tandospirone is an effective and safe anti-anxiety drug for adolescents.
Department of Psychiatrics, Second Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou 310005, China.
Ming
M
Tao
Yao-jing
YJ
Han
Jing-fang
JF
Gao
Wen-xin
WX
Tang
Xiang-zhen
XZ
Zhu
Dan-hong
DH
Tao
Ping
P
Zhang
Ying
Y
Zou
Hua
H
Chen
Shu-fei
SF
Tao
D000293:Adolescent; D014151:Anti-Anxiety Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000188:drug therapy*; D005260:Female; D006801:Humans; D054833:Isoindoles / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D055815:Young Adult
D014151:Anti-Anxiety Agents; D054833:Isoindoles; D010879:Piperazines; D011743:Pyrimidines; C055267:tandospirone